We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Growing European Demand for Mad Cow Test

By HospiMedica staff writers
Posted on 29 Jan 2001
U.S. More...
company Bio-Rad Laboratories (Hercules, CA) has become a leading provider of tests for bovine spongiform encephalopathy (BSE) in Europe. The company reports it has received orders for more than one million enzyme-linked immunosorbent assays (ELISA) for BSE, known as mad cow disease.

Since October 2000, the fear of BSE has spread quickly throughout Europe, as more cattle were found with the disease. Cows with BSE have been discovered in France, Germany, Spain, Portugal, and Italy. On January 1, 2001, the countries of the European Union commenced mandatory testing of all beef livestock over the age of 30 months in order to insure the highest quality and safety of the European food chain. According to media reports, seven million cattle will have to be tested in Europe this year.

Called Platelia, Bio-Rad's test was selected by the European Commission (EC) as one of the three most sensitive BSE tests and is among the three approved in the most recent EC report. Two independent reports commissioned by a directorate of the EC further substantiated Bio-Rad's test as the preferred test for diagnosing BSE in European cattle. The test is in a screening format for use in high throughput environments, providing results in about four hours.

To meet the demand for tests, Bio-Rad has increased manufacturing capabilities at its French facilities and is mobilizing employees around the world to support the scaling up of production. "We have allocated substantial resources to ensure that we can rapidly meet the growing needs for a quick, clear, and accurate test,” said David Schwartz, president and CEO of Bio-Rad.



Related Links:
Bio-Rad

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.